After a start-up financing of CHF 0.4 Mio in 1998, the Company became fully operational upon the closing of its Series A financing round in May 2000, which raised a total of CHF 10.5 Mio in equity. This financing round was co-led by Nextech Venture and Novartis Venture Fund and substantially backed by BPP Business Promotion Partners (all from Switzerland).

To enable the further advancement of its cancer program and to finance the acquisition of the core assets of CallistoGen AG and Abeta GmbH (both from Germany), the Company completed a CHF 14 Mio Series B financing round in November 2003. While this financing round received continuing support from the existing shareholders, new investors like Najeti Capital, a leading Spanish venture capital firm from Madrid, Heidelberg Innovation of Heidelberg, Germany and several high net worth individuals could be attracted.

A Series C financing round with a volume of CHF 25.5 Mio has been closed in February 2005 and allows for the full exploitation of the potentials of the Company’s two therapeutic programs and its Alzheimer diagnostic business. While a total of CHF 17.5 Mio has been committed upfront, an additional installment of CHF 8 Mio is associated with the achievement of certain development milestones in 2007. This financing round was co-led by Nextech Venture, Novartis Venture Fund and a major new investor, Varuma AG of Basel.